Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The latest analyst coverage could presage a bad day for Esperion Therapeutics, Inc. ( NASDAQ:ESPR ), with the analysts...
An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.